OBJECTIVE: To examine whether plasma markers of amyloid precursor protein metabolism (amyloid beta-protein ending in Val-40 [Abeta40] and Ala-42 [Abeta42]), inflammation (high-sensitivity C-reactive protein), and folic acid metabolism (folic acid, vitamin B(12), and total homocysteine levels) are associated with the rate of cognitive and functional decline in persons with Alzheimer disease. DESIGN: Longitudinal study across a mean (SD) of 4.2 (2.6) years with assessments at approximately 6- to 12-month intervals. SETTING: Outpatient care. PATIENTS: A cohort of 122 patients having a clinical diagnosis of probable Alzheimer disease, each with at least 2 assessments across time. MAIN OUTCOME MEASURES: Scores on the cognitive Information-Memory-Concentration subscale of the Blessed Dementia Scale and the functional Weintraub Activities of Daily Living Scale. RESULTS: Low plasma levels of Abeta40, Abeta42, and high-sensitivity C-reactive protein were associated with a significantly more rapid cognitive decline, as indexed using the Blessed Dementia Scale, than were high levels. Low levels of Abeta42 and high-sensitivity C-reactive protein were significantly associated with more rapid functional decline on the Weintraub Activities of Daily Living Scale than were high levels. These plasma markers contributed about 5% to 12% of the variance accounted for on the Blessed Dementia Scale and the Activities of Daily Living Scale by fixed-effects predictors. Measures of folic acid metabolism were not associated with changes on either the Blessed Dementia Scale or the Activities of Daily Living Scale. CONCLUSIONS: Plasma markers of amyloid precursor protein metabolism and C-reactive protein may be associated with the rate of cognitive and functional decline in patients with Alzheimer disease.
OBJECTIVE: To examine whether plasma markers of amyloid precursor protein metabolism (amyloid beta-protein ending in Val-40 [Abeta40] and Ala-42 [Abeta42]), inflammation (high-sensitivity C-reactive protein), and folic acid metabolism (folic acid, vitamin B(12), and total homocysteine levels) are associated with the rate of cognitive and functional decline in persons with Alzheimer disease. DESIGN: Longitudinal study across a mean (SD) of 4.2 (2.6) years with assessments at approximately 6- to 12-month intervals. SETTING:Outpatient care. PATIENTS: A cohort of 122 patients having a clinical diagnosis of probable Alzheimer disease, each with at least 2 assessments across time. MAIN OUTCOME MEASURES: Scores on the cognitive Information-Memory-Concentration subscale of the Blessed Dementia Scale and the functional Weintraub Activities of Daily Living Scale. RESULTS: Low plasma levels of Abeta40, Abeta42, and high-sensitivity C-reactive protein were associated with a significantly more rapid cognitive decline, as indexed using the Blessed Dementia Scale, than were high levels. Low levels of Abeta42 and high-sensitivity C-reactive protein were significantly associated with more rapid functional decline on the Weintraub Activities of Daily Living Scale than were high levels. These plasma markers contributed about 5% to 12% of the variance accounted for on the Blessed Dementia Scale and the Activities of Daily Living Scale by fixed-effects predictors. Measures of folic acid metabolism were not associated with changes on either the Blessed Dementia Scale or the Activities of Daily Living Scale. CONCLUSIONS: Plasma markers of amyloid precursor protein metabolism and C-reactive protein may be associated with the rate of cognitive and functional decline in patients with Alzheimer disease.
Authors: Helga Refsum; A David Smith; Per M Ueland; Ebba Nexo; Robert Clarke; Joseph McPartlin; Carole Johnston; Frode Engbaek; Jørn Schneede; Catherine McPartlin; John M Scott Journal: Clin Chem Date: 2004-01 Impact factor: 8.327
Authors: K Yaffe; K Lindquist; B W Penninx; E M Simonsick; M Pahor; S Kritchevsky; L Launer; L Kuller; S Rubin; T Harris Journal: Neurology Date: 2003-07-08 Impact factor: 9.910
Authors: Marianne J Engelhart; Mirjam I Geerlings; John Meijer; Amanda Kiliaan; Annemieke Ruitenberg; John C van Swieten; Theo Stijnen; Albert Hofman; Jacqueline C M Witteman; Monique M B Breteler Journal: Arch Neurol Date: 2004-05
Authors: A Assini; S Cammarata; A Vitali; M Colucci; L Giliberto; R Borghi; M L Inglese; S Volpe; S Ratto; F Dagna-Bricarelli; C Baldo; A Argusti; P Odetti; A Piccini; M Tabaton Journal: Neurology Date: 2004-09-14 Impact factor: 9.910
Authors: M Ingelsson; H Fukumoto; K L Newell; J H Growdon; E T Hedley-Whyte; M P Frosch; M S Albert; B T Hyman; M C Irizarry Journal: Neurology Date: 2004-03-23 Impact factor: 9.910
Authors: M E Soto; S Andrieu; C Arbus; M Ceccaldi; P Couratier; T Dantoine; J-F Dartigues; S Gillette-Guyonnet; F Nourhashemi; P-J Ousset; M Poncet; F Portet; J Touchon; B Vellas Journal: J Nutr Health Aging Date: 2008-12 Impact factor: 4.075
Authors: James R Hall; Leigh A Johnson; Robert C Barber; Hoa T Vo; A Scott Winter; Sid E O'Bryant Journal: J Alzheimers Dis Date: 2012 Impact factor: 4.472
Authors: Jon B Toledo; Hugo Vanderstichele; Michal Figurski; Paul S Aisen; Ronald C Petersen; Michael W Weiner; Clifford R Jack; William Jagust; Charles Decarli; Arthur W Toga; Estefanía Toledo; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski; Leslie M Shaw Journal: Acta Neuropathol Date: 2011-07-30 Impact factor: 17.088
Authors: Fei Song; Anne Poljak; Michael Valenzuela; Richard Mayeux; George A Smythe; Perminder S Sachdev Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: Sid E O'Bryant; Stephen C Waring; Valerie Hobson; James R Hall; Carol B Moore; Teodoro Bottiglieri; Paul Massman; Ramon Diaz-Arrastia Journal: J Geriatr Psychiatry Neurol Date: 2009-11-20 Impact factor: 2.680